Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Facilitated Transport01:19

Facilitated Transport

148.0K
The chemical and physical properties of plasma membranes cause them to be selectively permeable. Since plasma membranes have both hydrophobic and hydrophilic regions, substances need to be able to transverse both regions. The hydrophobic area of membranes repels substances such as charged ions. Therefore, such substances need special membrane proteins to cross a membrane successfully. In  facilitated transport, also known as facilitated diffusion, molecules and ions travel across a...
148.0K
Facilitated Transport01:19

Facilitated Transport

18.7K
The chemical and physical properties of plasma membranes cause them to be selectively permeable. Since plasma membranes have both hydrophobic and hydrophilic regions, substances need to be able to transverse both regions. The hydrophobic area of membranes repels substances such as charged ions. Therefore, such substances need special membrane proteins to cross a membrane successfully. In  facilitated transport, also known as facilitated diffusion, molecules and ions travel across a...
18.7K
Social Facilitation01:04

Social Facilitation

36.6K
Not all intergroup interactions lead to negative outcomes. Sometimes, being in a group situation can improve performance. Social facilitation occurs when an individual performs better when an audience is watching than when the individual performs the behavior alone. This typically occurs when people are performing a task for which they are skilled.
36.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human stem cell-based embryo models: innovation, ethics, and policy.

Human reproduction (Oxford, England)·2026
Same author

Fifty years of the Congenital Disabilities (Civil Liability) Act 1976: A spent statute?

Medical law review·2026
Same author

What's in a name? Abbasi and Another v Newcastle upon Tyne Hospitals NHS Foundation Trust; Haastrup v King's College Hospital NHS Foundation Trust [2025] UKSC 15.

Medical law review·2026
Same author

How should we decide how to treat the child: harm versus best interests in cases of disagreement.

Medical law review·2023
Same author

Should states restrict recipient choice amongst relevant and available COVID-19 vaccines?

Medical law review·2022
Same author

Involving parents in paediatric clinical ethics committee deliberations: a current controversy.

Journal of medical ethics·2022

Related Experiment Video

Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

EU Clinical Trials Regulation 2014: Fetter or facilitator?

Emma Cave1

  • 1Durham University, UK.

Medical Law International
|January 1, 2019
PubMed
Summary

The EU Clinical Trials Regulation streamlines applications and enhances transparency. Post-Brexit, the UK

Area of Science:

  • Regulatory science
  • Clinical trial management
  • European Union law

Background:

  • The European Union (EU) Clinical Trials Regulation 536/2014 aims to simplify cross-border clinical trials and improve results transparency.
  • The UK's regulatory status regarding this Regulation post-Brexit remains uncertain, contingent on future EU-UK relationship agreements.
  • EU life sciences regulations will be converted into UK law via the EU (Withdrawal) Act.

Purpose of the Study:

  • To analyze the implications of Brexit on the implementation of the EU Clinical Trials Regulation in the UK.
  • To discuss the UK's potential need to comply with the International Council on Harmonisation framework for medicinal product trials.
  • To advocate for regulatory harmonization with the EU, contrasting it with a deregulated approach.

Main Methods:

Keywords:
BrexitClinical trialshealthcare researchlife sciencesregulation

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K
  • Review of the EU Clinical Trials Regulation 536/2014 and related EU legislation.
  • Analysis of the potential impact of Brexit on UK clinical trial regulations.
  • Examination of the International Council on Harmonisation guidelines.

Main Results:

  • The Regulation's implementation in the UK is likely to occur post-Brexit but within a transition period.
  • The UK may need to adhere to International Council on Harmonisation standards if not part of the EU's legal framework.
  • Harmonization with EU regulations is presented as advantageous over a bespoke, deregulated model.

Conclusions:

  • The UK's regulatory alignment with the EU for clinical trials post-Brexit requires careful consideration.
  • Maintaining harmonization with the EU framework is crucial for continued participation in European clinical trials.
  • A harmonized approach offers benefits that may outweigh a deregulated strategy for the UK's clinical research landscape.